 "AstraZeneca to shut down API unit in Bengaluru")
AstraZeneca Pharma India will to close the active pharmaceutical ingredient (API) manufacturing unit at its Bengaluru site as the company has decided to stop the production of terbutaline sulphate – the only product being manufactured at the unit. However, the company’s tablet manufacturing plant, which started commercial operations in 2013, will continue to operate at this site, said AstraZeneca in a BSE filing on December 3, 2015.
The decision (to close down API unit) was taken following an application to the Drug Controller General of India (DCGI) to withdraw the manufacturing licence for TBS, said AstraZeneca Pharma India. The product was manufactured primarily for export and the company applied to withdraw the licence following low demand in the export markets.
“The Board took the decision as terbutaline sulphate (TBS) was the last API to be manufactured at the API unit and no other API manufacturing activity is planned to be carried out at this unit in the future,” the company said.
Terbutaline sulphate is used in formulations that are used to treat bronchospasm in patients with asthma and reversible bronchospasm associated with bronchitis and emphysema.
The decision (to close down API unit) was taken following an application to the Drug Controller General of India (DCGI) to withdraw the manufacturing licence for TBS, said AstraZeneca Pharma India. The product was manufactured primarily for export and the company applied to withdraw the licence following low demand in the export markets.
“The Board took the decision as terbutaline sulphate (TBS) was the last API to be manufactured at the API unit and no other API manufacturing activity is planned to be carried out at this unit in the future,” the company said.
Terbutaline sulphate is used in formulations that are used to treat bronchospasm in patients with asthma and reversible bronchospasm associated with bronchitis and emphysema.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%